1. Home
  2. SHLS vs REPL Comparison

SHLS vs REPL Comparison

Compare SHLS & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shoals Technologies Group Inc.

SHLS

Shoals Technologies Group Inc.

HOLD

Current Price

$7.64

Market Cap

1.3B

Sector

Technology

ML Signal

HOLD

Logo Replimune Group Inc.

REPL

Replimune Group Inc.

HOLD

Current Price

$11.90

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SHLS
REPL
Founded
1996
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.3B
IPO Year
2020
2018

Fundamental Metrics

Financial Performance
Metric
SHLS
REPL
Price
$7.64
$11.90
Analyst Decision
Buy
Buy
Analyst Count
19
8
Target Price
$11.11
★ $19.50
AVG Volume (30 Days)
★ 3.7M
1.8M
Earning Date
11-04-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 42.86
N/A
EPS
★ 0.07
N/A
Revenue
★ $475,331,000.00
N/A
Revenue This Year
$31.77
N/A
Revenue Next Year
$11.99
$497.81
P/E Ratio
$114.57
★ N/A
Revenue Growth
★ 19.07
N/A
52 Week Low
$5.55
$1.50
52 Week High
$13.18
$16.33

Technical Indicators

Market Signals
Indicator
SHLS
REPL
Relative Strength Index (RSI) 46.48 43.76
Support Level $6.66 $6.81
Resistance Level $7.66 $12.50
Average True Range (ATR) 0.46 0.69
MACD -0.08 -0.08
Stochastic Oscillator 33.69 41.13

Price Performance

Historical Comparison
SHLS
REPL

About SHLS Shoals Technologies Group Inc.

Shoals Technologies Group is a provider of electrical balance of system solutions for solar energy projects, primarily in the United States. EBOS encompasses components that are necessary to carry electric current produced by solar panels to an inverter. The products are sold principally to engineering, procurement, and construction firms that build solar energy projects.

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.

Share on Social Networks: